LPTX News and Press, Leap Therapeutics Inc. From 01/17/23

Leap Therapeutics Acquires Flame Biosciences PR Newswire Adds FL-301, clinical stage anti-Claudin18.2 antibody, and two preclinical antibody programs to Leap's pipeline Combined cash balance of approximately $115 million enhances runway to mid-2025, fully-funding a...

Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference PR Newswire CAMBRIDGE, Mass. , Jan. 11, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology the...

Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Nov. 21, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-o...

The following slide deck was published by Leap Therapeutics, Inc. in conjunction with this event. For further details see: Leap Therapeutics,(LPTX) Investor Presentation - Slideshow

Leap Therapeutics press release ( NASDAQ: LPTX ): Q3 GAAP EPS of -$0.13 misses by $0.01 . Net Loss was $15.1 million for the third quarter 2022 For further details see: Leap Therapeutics GAAP EPS of -$0.13 misses by $0.01

Leap Therapeutics Reports Third Quarter 2022 Financial Results PR Newswire CAMBRIDGE, Mass. , Nov. 14, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, to...

Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients PR Newswire CAMBRIDGE, Mass. , Oct. 17, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology compan...

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer PR Newswire CAMBRIDGE, Mass. , Oct. 12, 2022 /PRNewswire/...

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting PR Newswire CAMBRIDGE, Mass. , Oct. 5, 2022 /PRNewswire/ -- Leap Therapeutics, Inc...

SAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science o...